Abstract Number: 1920 • ACR Convergence 2020
Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis and Visual Impairment
Background/Purpose: Tocilizumab (TCZ) represents a potent new therapeutic principle for patients with GCA, however, data on efficacy and safety in patients who present with visual…Abstract Number: 0518 • ACR Convergence 2020
The Impact of Large Vessel Vasculitis of the Axillary Artery on Cumulative Glucocorticoid Dose and Relapse Rate in Giant Cell Arteritis
Background/Purpose: Prognostic markers for clinical outcomes in giant cell arteritis (GCA) are urgently needed. While large vessel GCA (LV-GCA) has been associated with higher glucocorticoid…Abstract Number: 1927 • ACR Convergence 2020
Ultrasonographic Halo Score as a Marker for Diagnosis and Monitoring of Disease Activity in GCA
Background/Purpose: EULAR recommendations highlights ultrasound (US) as the first line imaging investigation for giant cell arteritis (GCA). Traditionally, the halo sign and compression sign have…Abstract Number: 0850 • ACR Convergence 2020
What Does It Mean to Be a BICLA (BILAG-Based Composite Lupus Assessment) Responder? Post Hoc Analysis of the Phase 3 TULIP-1 and TULIP-2 Trials
Background/Purpose: BICLA is a validated composite global measure of SLE disease activity that incorporates BILAG, an instrument that distinguishes between partial and complete improvement. BICLA…Abstract Number: 1931 • ACR Convergence 2020
Effect of Cumulative Glucocorticoid Dose and Inflammation on Weight Change During Treatment of Giant Cell Arteritis
Background/Purpose: Giant cell arteritis (GCA) is a form of large vessel vasculitis that requires treatment with high-dose, long-term glucocorticoids (GC). Weight gain, among other side-effects…Abstract Number: 2694 • 2019 ACR/ARP Annual Meeting
Inpatient Treatment Variation in New-Onset Systemic Juvenile Idiopathic Arthritis
Background/Purpose: The effectiveness of IL-1 and IL-6 inhibitors as first-line therapy in patients with new-onset systemic JIA has led to the concept of a “window…Abstract Number: 2825 • 2019 ACR/ARP Annual Meeting
Provider Variability in Glucocorticoid Prescribing for Patients with Rheumatoid Arthritis and Impact on Chronic Glucocorticoid Use
Background/Purpose: Glucocorticoids are recommended as short-term bridging therapy in patients with rheumatoid arthritis (RA), but as many as 30-40% of patients remain on glucocorticoids chronically.…Abstract Number: 554 • 2019 ACR/ARP Annual Meeting
Evidence to Guide Glucocorticoid Tapering Is Lacking in RA
Background/Purpose: Over a third of RA patients are managed with long-term oral glucocorticoids (GC), defined as daily GC use for ≥3 months[1]. Due to dose-dependent…Abstract Number: 848 • 2019 ACR/ARP Annual Meeting
Risk of Serious Infection with Long-Term Use of Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis
Background/Purpose: As many as 30-40% of patients with RA remain on long term glucocorticoids. Infection risk with higher dose glucocorticoids is well known, but evidence…Abstract Number: 1152 • 2019 ACR/ARP Annual Meeting
Low Rates of Bone Mineral Density Testing by Rheumatologists in Patients with Systemic Lupus Erythematosus and Glucocorticoid Therapy
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are at an increased risk of developing osteoporosis and clinical fractures compared to healthy controls. Bone loss in…Abstract Number: 1432 • 2019 ACR/ARP Annual Meeting
Tapering and Discontinuing Prednisolone Without Deteriorated Disease Control by Optimizing Methotrexate in Patients with Rheumatoid Arthritis Under Stable Treatment – 2-year Results in the Real-world Clinical Practice –
Background/Purpose: To determine whether prednisolone (PSL) could be tapered or discontinued without deterioration of disease control through optimizing methotrexate (MTX) for 2-yrs in patients with…Abstract Number: 1665 • 2019 ACR/ARP Annual Meeting
Glucocorticoids in Incident ANCA-Associated Vasculitis (AAV) Patients – A Study of Routine Clinical Practice in the EU Demonstrates Prolonged Use and Temporal Relationship to Adverse Events and Infections
Background/Purpose: AAV is a severe systemic vasculitis and rapid induction of remission is essential and high dose glucocorticoids (GC) are part of standard of care.…Abstract Number: 1666 • 2019 ACR/ARP Annual Meeting
Maintenance Treatment in ANCA Associated Vasculitis in Real World Clinical Practice – Burden of Disease, Use of Glucocorticoids and Impact on Patient Functional Status Remain Major Problems
Background/Purpose: After successful remission induction AAV is a relapsing remitting long term condition and patients are at risk of organ damage from both active AAV…Abstract Number: 1876 • 2019 ACR/ARP Annual Meeting
Effect of Discontinuation of Denosumab in Subjects with Rheumatoid Arthritis Treated with Glucocorticoids
Background/Purpose: Denosumab, a monoclonal antibody against RANKL, is approved for the treatment of glucocorticoid (GC) induced osteoporosis (GiOP). In postmenopausal women with osteoporosis, denosumab discontinuation…Abstract Number: 2219 • 2019 ACR/ARP Annual Meeting
Randomized Control Study in Glucocorticoid-Induced Osteoporosis Treated with Bisphosphonate or Denosumab (GOBID)
Background/Purpose: It has not been established which therapy, bisphosphonates or denosumab, is more effective for glucocorticoid-induced osteoporosis (GIO). The purpose of this study was to…
- « Previous Page
- 1
- …
- 12
- 13
- 14
- 15
- 16
- …
- 22
- Next Page »